Tri-Con 2014 - EKF diagnostic GmbH Molecular To Showcase PointMan DNA-Enrichment Kits
Cardiff, UK – 10th February 2014 – EKF Diagnostics (www.ekfdiagnostics.com), the global in vitro diagnostics business, announces that its subsidiary company EKF Molecular Diagnostics is exhibiting its ground-breaking PointMan™ DNA-enrichment technology at Tri-Con 2014 in San Francisco, CA, Booth #417, 10-14th February.
PointMan is a real-time PCR technology that provides reliable and extremely sensitive detection of cancer-related mutations. Fully compatible with industry standard instruments and DNA extraction methods, it is highly specific and efficient in amplifying the target sequence, while simultaneously suppressing amplification of the wild-type. The resulting sample is effectively enriched for the mutation, providing industry-leading sensitivity across a wide variety of sample types, including whole blood.
PointMan’s landmark ability to enrich low-level DNA mutations from whole blood is the focus of an ongoing collaboration between EKF Molecular Diagnostics and the Institute of Life Sciences at Swansea University. Recent preliminary results from a study of samples archived in the Wales Cancer Bank, have demonstrated that PointMan technology could enable non-invasive blood based testing and reduce the need for tumor biopsies for cancer patient mutation status assessment.
Personnel from EKF Molecular Diagnostics will be on hand at Tri-Con 2014 to demonstrate and discuss the effectiveness of EKF Molecular's portfolio of PointMan DNA enrichment kits that detect mutations for cancer biomarkers including: BRAF, KRAS, EGFR, NRAS and JAK2. These genes are associated with skin melanoma, colorectal and lung cancers, as well as myeloma.
The 21st International Molecular Medicine Tri-Conference will focus on Drug Discovery, Genomics, Diagnostics and Information Technology. “Tri-Con 2014 provides an ideal platform to feature our growing range of products and technologies developed to meet an increasing demand for superior sensitivity and specificity in molecular diagnostics,” said Andrew Webb, CEO, EKF Molecular Diagnostics.
For more information on EKF Diagnostics, please visit www.ekfdiagnostics.com.
About EKF Diagnostics
www.ekfdiagnostics.com
EKF Diagnostics Holdings plc specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new Molecular division focuses on molecular and companion diagnostics.
Companion Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics - EKF Molecular Diagnostics develops technologies for cancer gene detection. Through its acquisition of UK-based 360 Genomics and by offering innovative products with the potential to change current DNA extraction and detection practices, EKF is addressing the fast growing companion diagnostics market.
Point-of-care diagnostics: EKF Diagnostics’ expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to liquid reagent manufacture, design and building of world-class diagnostic devices, and distribution of rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
EKF Diagnostics products are sold in more than 100 countries around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.
Help employers find you! Check out all the jobs and post your resume.